Proteome completes third milestone in TB program with international non-profit partner

By Lisa Kerner

Charlotte, N.C., June 26 - Proteome Systems said it has completed the characterization of multiple Mycobacterium tuberculosis (M.tb) proteins in a pilot study of M.tb positive and negative clinical samples.

This marks the third milestone the company has met in its tuberculosis program in conjunction with its international partner, the Foundation for Innovative New Diagnostics (FIND).

"We are very pleased with the progress we are making on the development of a rapid test to detect active TB," Proteome chief executive officer Stephen Porges said in a company news release.

"Our goal is to have a test ready for analysis in laboratories of both the developing and developed world by first quarter 2007."

FIND is providing Proteome with clinical material, assistance with clinical trials and fast tracking registration in exchange for rights to use its antibodies in public health products.

Proteome is a medical technology company specializing in respiratory disease, neurobiology and aging, cancer and infectious diseases.

FIND is a non-profit Swiss foundation based in Geneva that supports and promotes the health of people in developing countries.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.